1. Classification of the four main types of lung cancer using a microRNA-based diagnostic assay
- Author
-
Nir Dromi, Ranit Aharonov, Iris Barshack, Sima Benjamin, Irit Krivitsky, Ilanit Burnstein, Laurie Horowitz, Yajue Huang, Craig Thurm, J. Steve Hou, Michal Kushnir, Marluce Bibbo, Shlomit Gilad, Meora Feinmesser, Gila Lithwick-Yanai, Brianna St. Cyr, Hadas Gibori, Mats Sanden, and Tina Bocker Edmonston
- Subjects
Oncology ,medicine.medical_specialty ,Lung Neoplasms ,Small-cell carcinoma ,Bronchial brushing ,Sensitivity and Specificity ,Pathology and Forensic Medicine ,Internal medicine ,microRNA ,medicine ,Humans ,Typing ,Lung cancer ,Oligonucleotide Array Sequence Analysis ,Lung ,business.industry ,Gene Expression Profiling ,Reproducibility of Results ,medicine.disease ,Gene expression profiling ,Gene Expression Regulation, Neoplastic ,MicroRNAs ,medicine.anatomical_structure ,Molecular Diagnostic Techniques ,Immunology ,Molecular Medicine ,Non small cell ,business - Abstract
For patients with primary lung cancer, accurate determination of the tumor type significantly influences treatment decisions. However, techniques and methods for lung cancer typing lack standardization. In particular, owing to limited tumor sample amounts and the poor quality of some samples, the classification of primary lung cancers using small preoperative biopsy specimens presents a diagnostic challenge using current tools. We previously described a microRNA-based assay (miRview squamous; Rosetta Genomics Ltd., Rehovot, Israel) that accurately differentiates between squamous and nonsquamous non–small cell lung cancer. Herein, we describe the development and validation of an assay that differentiates between the four main types of lung cancer: squamous cell carcinoma, nonsquamous non–small cell lung cancer, carcinoid, and small cell carcinoma. The assay, miRview lung (Rosetta Genomics Ltd.), is based on the expression levels of eight microRNAs, measured using a sensitive quantitative RT-PCR platform. It was validated on an independent set of 451 samples, more than half of which were preoperative cytologic samples (fine-needle aspiration and bronchial brushing and washing). The assay returned a result for more than 90% of the samples with overall accuracy of 94% (95% CI, 91% to 96%), with similar performance observed in pathologic and cytologic samples. Thus, miRview lung is a simple and reliable diagnostic assay that offers an accurate and standardized classification tool for primary lung cancer using pathologic and cytologic samples.
- Published
- 2011